PP
SUPN icon

PDT Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

PDT Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.2M Sell
25,858
-50,815
-66% -$2.44M 0.06% 301
2026
Q1 		$3.96M Hold
76,673
– – 0.23% 142
2025
Q4 		$3.81M Sell
76,673
-11,600
-13% -$564K 0.25% 147
2025
Q3 		$4.22M Sell
88,273
-6,034
-6% -$243K 0.27% 136
2025
Q2 		$2.97M Buy
94,307
+56,926
+152% +$1.82M 0.17% 210
2025
Q1 		$1.22M Sell
37,381
-17,627
-32% -$625K 0.09% 357
2024
Q4 		$1.99M Buy
55,008
+17,898
+48% +$630K 0.18% 205
2024
Q3 		$1.16M Buy
+37,110
New +$1.16M 0.1% 331
2024
Q2 		– Sell
-49,030
Closed -$1.67M – 745
2024
Q1 		$1.67M Buy
+49,030
New +$1.46M 0.16% 227
2023
Q1 		– Sell
-44,646
Closed -$1.59M – 712
2022
Q4 		$1.59M Buy
44,646
+12
+0% +$417 0.26% 132
2022
Q3 		$1.51M Sell
44,634
-21,309
-32% -$693K 0.23% 117
2022
Q2 		$1.91M Buy
+65,943
New +$1.89M 0.17% 185
2020
Q2 		– Sell
-28,550
Closed -$514K – 819
2020
Q1 		$514K Buy
28,550
+13,512
+90% +$284K 0.04% 363
2019
Q4 		$357K Buy
+15,038
New +$365K 0.02% 495
2016
Q3 		– Sell
-97,600
Closed -$1.99M – 511
2016
Q2 		$1.99M Hold
97,600
– – 0.16% 199
2016
Q1 		$1.49M Sell
97,600
-16,100
-14% -$210K 0.09% 267
2015
Q4 		$1.53M Buy
113,700
+16,100
+16% +$249K 0.21% 172
2015
Q3 		$1.37M Sell
97,600
-600
-0.6% -$11.2K 0.03% 609
2015
Q2 		$1.67M Buy
98,200
+50,659
+107% +$721K 0.04% 504
2015
Q1 		$575K Buy
+47,541
New +$449K 0.01% 961
2014
Q2 		– Sell
-21,539
Closed -$193K – 1620
2014
Q1 		$193K Buy
+21,539
New +$198K ﹤0.01% 1237

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

PDT Partners's SUPN Position: Q2 2026 in Review

PDT Partners reduced its Supernus Pharmaceuticals (SUPN) stake by 66% in Q2 2026, selling an estimated $2.44M and leaving 25,858 shares worth $1.2M. The position accounts for 0.06% of the portfolio, ranked #301.

PDT Partners first reported a position in SUPN in Q1 2014 and has held it in 21 quarters since. The position peaked at $4.22M in Q3 2025. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • PDT Partners held 25,858 shares of Supernus Pharmaceuticals worth $1.2M as of Q2 2026.
  • PDT Partners sold 50,815 Supernus Pharmaceuticals shares in Q2 2026, an estimated $2.44M.
  • Supernus Pharmaceuticals made up 0.06% of PDT Partners's portfolio in Q2 2026, its #301 holding.
  • PDT Partners first reported a position in Supernus Pharmaceuticals in Q1 2014 and has held it in 21 quarters since.
  • PDT Partners's Supernus Pharmaceuticals position peaked at $4.22M in Q3 2025.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on PDT Partners's 13F filing for Q2 2026, filed 14 Aug 2026.